Related Experiment Video
Updated: Jul 15, 2026
06:59
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Indications for biotherapy in systemic vasculitides
Loïc Guillevin1, Christian Pagnoux, Philippe Guilpain
1Department of Internal Medicine, French Vasculitis Study Group, Centre de Référence Vascularites et Sclérodermie, Hôpital Cochin, Université Paris Descartes, Paris, France. loic.guillevin@cch.aphp.fr
Clinical Reviews in Allergy & Immunology
|April 12, 2007
Summary
Biotherapy offers new treatments for systemic vasculitis, including targeted monoclonal antibodies. Ongoing trials will clarify their role as first-line therapy for refractory cases.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Biotherapy is an established treatment for systemic vasculitides.
- Cytokines like interferon and polyvalent immunoglobulin (IVIg) have defined roles.
- Newer targeted monoclonal antibodies are emerging for specific vasculitis types.
Purpose of the Study:
- To review the current role of biotherapy in systemic vasculitides.
- To discuss the application of targeted monoclonal antibodies.
- To highlight the need for further research on optimal usage and first-line indications.
Main Methods:
- Review of current literature on biotherapy for systemic vasculitides.
- Analysis of the use of cytokines and monoclonal antibodies.
- Discussion of ongoing clinical trials and future directions.
Main Results:
- Biotherapy, including interferon, IVIg, anti-TNF-alpha, anti-CD20, anti-IL-5, and anti-IgE, is used for systemic vasculitides.
- These agents are often reserved for refractory cases.
- Promising results are observed in patients with treatment-resistant disease.
Conclusions:
- Biotherapy has a defined place in managing systemic vasculitides.
- Targeted monoclonal antibodies show promise, particularly in refractory disease.
- Further research and ongoing trials are crucial to establish optimal indications, dosage, and duration, and to evaluate their potential as first-line treatments.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Endocarditis III: Medical Management
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...